ABIGAIL HAM: Open Payments
NPI 1528494051 · FLORENCE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,269 in 120 payments from 22 companies in 2025. Trend: 2023 $3,708 · 2024 $3,723 · 2025 $2,269
Food & beverage: $2,269
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 25 | $449 |
| ABBVIE INC. | 24 | $331 |
| UCB, Inc. | 12 | $217 |
| Biogen, Inc. | 8 | $176 |
| Neurocrine BioSciences, Inc. | 8 | $169 |
| PFIZER INC. | 6 | $112 |
| SK Life Science, Inc. | 3 | $99 |
| TG Therapeutics, Inc. | 4 | $94 |
| Mallinckrodt Hospital Products Inc. | 5 | $91 |
| Novartis Pharmaceuticals Corporation | 3 | $74 |
Products named: AUSTEDO XR, INGREZZA, UBRELVY, QULIPTA, LEQEMBI, NURTEC ODT, BRIUMVI, Fintepla.
Industry payments across SC — which companies pay providers there.
